Tyrosine kinase inhibitor discontinuation in non-allografted Philadelphia-positive acute lymphoblastic leukemia patients: a Campus ALL real-life study
Not available.
Saved in:
Main Authors: | Matteo Dragani, Michela Ansuinelli, Cristina Papayannidis, Nicola Fracchiolla, Valeria Cardinali, Michele Cedrone, Fabio Guolo, Salvatore Perrone, Prassede Salutari, Elisabetta Todisco, Robin Foà, Sabina Chiaretti |
---|---|
Format: | Article |
Language: | English |
Published: |
Ferrata Storti Foundation
2025-01-01
|
Series: | Haematologica |
Online Access: | https://haematologica.org/article/view/11897 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The combination of a tyrosine kinase inhibitor and blinatumomab in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia or Philadelphia chromosome‐like acute lymphoblastic leukemia
by: Xiaoxia Wu, et al.
Published: (2024-09-01) -
A young adult patient with Philadelphia positive acute lymphoblastic leukemia presenting with extreme hyperleukocytosis
by: Gulten Tikit, et al.
Published: (2025-01-01) -
An Unsuspected Finding of t(9;22): A Rare Case of Philadelphia Chromosome-Positive B-Lymphoblastic Lymphoma
by: Prajwal Boddu, et al.
Published: (2017-01-01) -
Recurrent Gastrointestinal Hemorrhage in Children with Philadelphia-Positive B-Cell Acute Lymphoblastic Leukemia Treated with Dasatinib: Case Reports
by: Xin Liao, et al.
Published: (2020-01-01) -
Molecular Monitoring in Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with the Variant e13a3 BCR-ABL1 Fusion
by: Mireille Crampe, et al.
Published: (2019-01-01)